Skip to main content

Poolbeg Pharma upbeat on preliminary influenza drug results

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

--News Direct--

Poolbeg Pharma PLC (OTCQB:POLBF) CEO Jeremy Skillington speaks to Proactive after announcing initial data analysis, including a 'clear dose-related response', for its drug, POLB 001, a potential treatment for severe influenza. Skillington says the 'early data readout' indicates that the challenge trial was successful.

Contact Details

Proactive UK Ltd

+44 20 7989 0813

uk@proactiveinvestors.com

View source version on newsdirect.com: https://newsdirect.com/news/poolbeg-pharma-upbeat-on-preliminary-influenza-drug-results-758545326

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Recent Quotes

View More
Symbol Price Change (%)
AMZN  251.59
+3.31 (1.33%)
AAPL  268.53
-4.52 (-1.66%)
AMD  277.49
+2.54 (0.92%)
BAC  54.02
+0.07 (0.13%)
GOOG  334.86
-0.54 (-0.16%)
META  671.42
+0.51 (0.08%)
MSFT  423.93
+5.86 (1.40%)
NVDA  200.99
-1.07 (-0.53%)
ORCL  182.48
+4.90 (2.76%)
TSLA  388.96
-3.54 (-0.90%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.